Indigenous Origins and Future Implications

This is the Guardian A stran ge scene, or perhaps better described as another strange scene, unfolded at the White House recently with President Donald Trump centre stage. He sat there at his desk in the Oval Office , and he's got a cast of characters behind him. Joe Rogan, who's a lot shorter actually, than many people may have thought, was sort of his head is like bobbing behind Trump . Joining Joe Rogan , the influential podcaster with an interest in alternative therapies, was a lawyer Brian Hubbard, who runs Americans for Ibiga ine, a kind of psychedelic that's had a lot of interest from the veteran community. And then there's a congressman next to him who took the psychedelics himself for his own war trauma . Just a few weeks before, Brian Hubbard, and former Texas Governor Rick Perry had done a podcast with Joe Rogan. They were just like, can you ask him, Joe? So Joe Rogan supposedly texts Trump and Trump responds almost immediately regarding the medicalization of this particular psychedelic ibigain. Great, sounds good. Do you want FDA approval ? And seemingly, just like that, they're on a fast track to review and approval. Today I'm pleased to announce historic reforms to dramatically accelerate access to new medical research and treatments based on psychedelic drugs psychedelics do remain illegal in the US class to Schedule 1 they're defined as drugs with no currently accepted medical use and a high potential for abuse. But this new executive order is a green light for researchers and pharmaceutical companies to explore the potential and risks of psychedelics as therapeutics. So today, has President Trump just opened the door to a psychedelic future ? From the Guardian, I'm Madeline Finley, and this is Science Weekly . Matha Busby, you're a journalist covering health, human rights and the environment. And you've written about Trump's recent executive order on psychedelics. Before we get into what it said, obviously these, are still tightly regulated drugs, but as studies on their potential therapeutic effects have begun to emerge, we've heard more voices calling for them to be made more accessible in research. Who's been campaigning on these drugs aside from the researchers themselves? At the forefront of it all really in the US are the veterans who are suffering from PTSD, traumatic brain injury and and really debilitating symptoms . And so they've emerged really as the key advocates for these reforms. And they've got the ear of lawmakers in the Republican Party and clearly now Trump. But you know, obviously psychedelics have long belonged to the cultural left for for decades . And it's just been interesting to see it kind of migrate rightwards here. And just to give a sense of the drugs we're talking about here, there are different psychedelics being studied like DMT, MDMA, and in fact there was an interesting study out last week looking at how a single dose of psilo cybin, the active ingredient in magic mushrooms can cause anatomical changes in the brain, and some of the participants even reported having a deeper sense of psychological insight and better wellbeing, but the only one specific ally called out in the executive order was something known as Ibigaine, which is probably the least studied of them all. It's been claimed to help those who've suffered traumatic brain injury or TBI. Tell me a bit more about this one. Ibigain is basically derived from Iboga , which is like this um root bark from a shrub that grows in Gabon principally , and it's the one that has really given relief to these veterans. They've been going down to Mexico in in their thousands . So there was a study a couple of years ago out of Stanford that was published in Nat ure, and they studied 30 combat veterans who were all suffering from debilitating TBI, and all of them experienced like a significant improvement in their symptoms. So this leads us on to the executive order. Give me the headlines of what it said. So there's sort of five or six elements to it and they're going to basically put, fifty million dollars into research, and it seems that a lot of it will be kind of corraled into studying this psychedelic ibigain. And then one of the key ones is that end of life pati ents will be given the right to try. And this is a sort of system that Trump actually introduced in his first term, and and he gave a long sort of monologue actually in the Oval Office about how proud he is of this. So it seems that yeah, Ibigaine won't be the kind of thing those patients will be doing, but psilo cybin, you know, maybe to like make peace with their deaf, which there has been research on, and then more widely they said that they're going to fast track the reviews of other psychedelics. So that's going to be two kinds of psilocybin drugs for two kinds of depression. And a lesser-known drug, methylen e, that's like a milder version of MDMA. And Trump said that any drugs that will be approved will then be rescheduled, so moved out of Schedule One, which he then followed up this meeting by down scheduling cannabis um a couple of weeks later. So yeah, you're really seeing a a flurry of things happening here. I mean, for a Republican president to be doing it as well is you, know, and and for it to be Trump, a man who says he's never even, you know, had a drink, had a trip, had a cigarette, is really far-fetched . I think I said in my piece you could be forgiven for thinking that you were hallucinating when you saw the scene it is really extraordinary and there's obviously been I got a call from a number of people, including the great Joe Rogan. And he said we have to do something about this. And I looked into it. I called Bobby, I called Oz, I called Marty and Jay , and it was really it was uniform support. How big would you say these influences are on Trump? I mean is this coming from the veterans or is it really sort of the power of podcasting? Yeah. To curry favour with it with this sort of like manosphere kind of Joe Rogan listener constituency, but yeah, at the same time it it was reported in the Washington Post that the executive order had already been being drafted up rather at at the time that Joe Rogan made this ask. Okay, so it's maybe more that this famously abstinent president has been pushed down this route through the advocacy of the veterans. But why now? I mean it was certainly a welcome distraction for him, right? Like at a time when they're clearly losing, not winning in Iran. But as I said earlier, I think the veteran stories are are really difficult to refute. Twenty two veterans are dying on average every day from suicide. He said in the Oval Office it's like twenty one times the amount of service people that have died on the battlefield since 9-11. So this is a really, really horrendous issue, and the drugs that these you know veterans are given to address their symptoms just often kind of get them addicted. And I think that there's you know shifting sands here and especially with the Make America Healthy movement, you know, there with with Kennedy and all these Maha mums, the mushroom mums behind them. There is there is a real fervor for change. And Matha, you make the point that this is also quite surprising coming during a Republican administration. I mean how big of a U turn does it represent for the Republic an Party? And where do things stand now amongst the administration? I'm sure there are many, many people in there who don't agree with what Trump is pushing forward. Yeah, I mean advocates fought, you know, especially with RFK in in as health secretary, who's obviously super pro psychedelic therapy, that, you know, stuff would have happened earlier. I mean there was a piece in Politico that said a few weeks before the executive order, the psychedelic revolution that never was, which obviously hasn't aged very well. But there's definitely been like a lot of discord between sort of Maha and MAGA people, you know, a lot of MAGA people, you know, really not interested in in furthering the cause of psychedelic therapy. So yeah, we kind of in in this really, really curious moment, Richard Nixon was the president that , you know, announced the war on drugs and and put these psychedelics into into Schedule One and then it was um Reagan's administration, I believe, that prohibited MDMA in the eighties. Yeah, you just wonder what sort of ripples this will have for the rest of the world, really, because it's it's been an American launched and led war on drugs, but it broadly does look like the war on drugs is is winding down significantly and that and this is you know another threshold moment to that. Yes. And of course psychedelics do remain illegal for the average person in the US. But what does it all mean in practice for researchers, for pharmaceutical companies and for those veteran advocates? I mean it's a huge green light, right? It's still very difficult to actually do psychedelic research quite often because of these um legal constraints. So once there is potentially an approval or two and a rescheduling, but that will also require the DEA , the Drug Enforcement Administration, to come on board. And only just before the executive order came out, there was a letter released that showed they were kind of, you know, against it . So there are moving parts here and it's it's kind of Trump almost sounding the starting gun or you know is certainly the biggest green light yet for a potential multi-billion dollar indust ry. You know, the the door has been pushed open far further than it ever has before, really . Coming up. The door may be opening, but who stands to gain I'm Kai Wright. I'm Carrie Sherman. And we are here to tell you about our new show, which is rooted in this feeling that at least I have, I know you have, where you know it's kind of like when you wake up in the morning and you pick up your phone and you're just hit in the face with a fire hose of news, right? Like there's war, there's authoritarianism, our planet is learning. I could go on and on and on. And on and on and on, but like we're trying to figure out how to manage it, right? Like how do you manage it? I manage it by leaning in and trying to learn more and trying to figure out, okay, how can I be smarter about this particular topic? And who can I talk to that's going to make me feel better about it? And who can tell me who's responsible for the mess that I'm reading about. So that's our mission. That's the show. Welcome to Stateside with Kai and Carter. We're a new show from The Guardian. We're talking to big thinkers and the best journalists, just trying to understand the world through smart conversation and honest reporting. We don't have billionaires telling us what to say. Stateside with Ky andle Carter will come out three times a week, Monday, Wednesday, and Friday starting May 13th. Follow on Apple Podcasts or catch us wherever you watch or listen. Metha, one of the aspects of this that you wrote about in your article was this element of indigenous communities having stewarded the use of these drugs, Ibigain in particular, and looking at Gabon as well, where it's designated a cultural heritage plant, what do we know about its origin as a drug? Yeah, so it's unclear exactly when it was discovered. There's a myth that it was a man and a woman hunted a porcupine and they cooked it into a ste w and the man had gone to sleep and his wife tried it and she started hallucinating. So it's unclear. I mean, certainly it's it must have been after the point that humans learned how to make soup. Um and so it was in the early 20th century then that French chemists were researching, I think it was an antidepressant drug of sorts, and so they extracted Ibigaine. And in the 60s, a man, Howard Lotsoff, who's addicted to heroin and was just experimenting with all sorts of other drugs on top of that. A chemist friend gave him some ibigaine and he took it and then, you know, almost miraculously, you know, woke up and realised he was wasn't in withdrawal for heroin. So you who owns Ibigain? There are concerns in in Gabon that folks aren't going to be kind of adequately compensated. The sovereign wealth fund uh of the country. They want a s a slice of the market. But equally Ibigain can be produced in labs. But yeah, certainly there are r real concerns that the advocates like behind Trump that day haven't kind of satisfactorily made a deal, what made any sort of deal with with the Gabonese people, even though Hubbard did sort of pay lip service and thanked our brothers in in Gabon for stewarding this medicine. And I suppose we'll see how that plays out and who ends up benefiting from it. Yeah, I mean immediately after the executive order it's the pharmaceutical companies whose stocks surged, who are developing psychedelic treatments until there is really like broad decriminalization, which there still hasn't been for cannabis, even you know, despite this latest um rescheduling, until that really happens, I I think that you know, advocates, at least left wing advocates will will be left sort of disappointed and, you know, even as it stands, they don't think Trump, you know, unsurprisingly, is is going to be the one that sort of delivers full liberation for, you know, these people, these psychonauts and and these plants. And I guess one of the lessons here as well is that if you've got a substance that you uh you want to be made available, get it in the inbox of Joe Rogan. I mean, really the conversation around psychedelics owes a lot to to him having kind of folks like Aubrey Marcus on his podcast , you know, more than a decade ago, and we you know, w the early kind of manosphere folks that were, you know, kind of giving a hall pass to to the listeners to be able to sort of go to the jungle and do ayahuasca and it and it not be considered a sort of lame thing to be doing . Well, as you say, I think it's very easy to kind of feel like you're looking at a a different world entirely when observing the Trump universe. So Maitha Busby thank you so much. Thanks very much . Thanks again to Maitha Busby. You can find his reporting at thegardian.com . And before you go, I just wanted to tell you about a video podcast that our New York office is launching. It's called Stateside with Kai and Carter, and it's hosted by our colleagues Kai Wright and Carter Sherman. Each week they're going to be trying to make sense of some of the biggest stories happening right now. The show will feature conversations with some of the smartest thinkers and reporters, not just from The Guardian, but from across the world. It's launching tomorrow, with episodes every Monday, Wednesday, and Friday. You can find it in full video on YouTube or wherever you get your podcasts . And that's all from us. This episode was produced by me Madeline Finley. The sound design was by Joel Cox and the executive producer was Ellie Bury . We'll be back on Thursday. See you then . This is the Guardian .